Anavex Life Sciences Corp (AVXL)

[nidan7500]

This is an example of what AVXL has needed. We would have liked to see this being said a few years ago instead of (Lilly) spending all that time and money, etc..

Anyways, this may indicate the kind of new knowledge we have waited for the BIG P guys to open up about instead of hanging on to the same ole Amyloid thesis crap.

This kind of new thinking had to happen before others would begin to look around and to begin to this..."Hey, IT's OK...sure we made mistakes in getting here but...the whole CELL clean up-waste thesis makes sense and BTW...It's OK to say that OUT LOUD. Funny, but that is how the system works sometimes. "If Lilly says it is OK, then guess it is OK to admit we were wrong all along. The root cause is further UPSTREAM right where AVXL says it was. Stand By.

The early indicator could have direct implications on future Alzheimer's treatments, given many of the current mechanisms target amyloid beta deposits outside of the cell. Biogen’s Aduhelm, for example, is a monoclonal antibody that binds to amyloid beta peptides to promote amyloid removal. Eli Lilly’s donanemab works similarly but targets the amyloid deposits themselves rather than the peptide. The latest research hints these both may not be targeting the root cellular problem that results in Alzheimer’s. The team concludes that it anticipates “broad potential” of its research “to facilitate assessment of autophagy/lysosome modulators as therapeutic agents.”

“This new evidence changes our fundamental understanding of how Alzheimer’s disease progresses,” said study senior investigator Ralph Nixon, M.D., Ph.D. “[I]t also explains why so many experimental therapies designed to remove amyloid plaques have failed to stop disease progression, because the brain cells are already crippled before the plaques fully form outside the cell.”

https://www.fiercebiotech.com/research/new-research-hints-alzheimers-treatments-may-be-hunting-down-amyloid-plaques-wrong-place